Nepal vs Senegal: Average cost of drugs for extensively drug-resistant tuberculosis
Nepal
2,853 constant 2022 US$
in 2024
Senegal
3,428 constant 2022 US$
in 2024
Nepal rank
21st
Senegal rank
20th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Nepal
- Senegal
How they compare
Senegal currently reports 3,428 constant 2022 US$ against 2,853 constant 2022 US$ in Nepal, a difference of 575 constant 2022 US$.
That makes Senegal's figure about 1.2 times Nepal's.
The two have swapped places 2 times across 5 shared years of data; in 2018 it was Senegal ahead.
Nepal ranks 21st and Senegal ranks 20th of 56 countries.
Across the 2 decades both report, Nepal averaged higher in 1 and Senegal in 1.
Head to head by decade
| Decade | Nepal | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,382 constant 2022 US$ | 5,308 constant 2022 US$ | 1,926 constant 2022 US$ | Senegal |
| 2020s | 3,050 constant 2022 US$ | 2,890 constant 2022 US$ | 160 constant 2022 US$ | Nepal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Nepal or Senegal?
- Senegal, at 3,428 constant 2022 US$ against 2,853 constant 2022 US$ in Nepal as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Nepal and Senegal?
- 575 constant 2022 US$, with Senegal ahead.
- How many years of comparable data are there for Nepal and Senegal?
- 5 years are reported by both, from 2018 to 2024.
- How do Nepal and Senegal rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Nepal ranks 21st and Senegal ranks 20th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.